What is CCP and anti CCP
Reading File
Finding Sources
Searching PubMed
"anti-CCP" AND "rheumatoid arthritis" AND diagnosis
Reading File
Finding Sources
Reading File
Reading File
Reading File
Here is a comprehensive explanation of CCP and anti-CCP:
CCP (Cyclic Citrullinated Peptide)
CCP refers to cyclic citrullinated peptides — synthetic peptides used as antigens in laboratory assays. They contain citrulline, an amino acid formed when arginine is post-translationally modified by an enzyme called peptidyl arginine deiminase (PAD). This process (citrullination) occurs during normal cell death and inflammation, but in genetically susceptible individuals, it triggers an autoimmune response.
Anti-CCP Antibodies
Anti-CCP (anti-cyclic citrullinated peptide antibodies) are autoantibodies that target these citrullinated proteins/peptides. They belong to a broader family called ACPA (anti-citrullinated protein/peptide antibodies), which includes:
- Antikeratin antibodies (AKA)
- Antiperinuclear factor (APF)
- Anti-Sa antibodies (targeting citrullinated vimentin)
- Anti-CCP (the most clinically used)
Clinical Significance — Rheumatoid Arthritis (RA)
Anti-CCP is primarily used in the diagnosis and prognostication of Rheumatoid Arthritis (RA).
Diagnostic Performance
| Parameter | Anti-CCP | Rheumatoid Factor (RF) |
|---|---|---|
| Sensitivity | ~69–70% | ~66–80% |
| Specificity | 95–98% | ~85% |
| Detection in early RA | ~50% (even when RF is negative) | Variable |
Anti-CCP is more specific than RF for RA, making it particularly useful when:
- The diagnosis is uncertain
- RF is negative (seronegative RA)
- Early diagnosis is needed before RF becomes positive
Prognostic Value
Positive anti-CCP is associated with:
- More erosive and severe disease
- Higher relapse rates
- Increased mortality
- Progressive joint destruction
Relationship to Risk Factors
Anti-CCP positivity is strongly linked to:
- Tobacco smoking
- The HLA "shared epitope" genetic marker (HLA-DR4)
Generations of Anti-CCP Testing
| Test | Year | Sensitivity | Specificity |
|---|---|---|---|
| 1st generation ELISA (anti-CCP1) | 1998 | ~50% | ~96% |
| 2nd generation ELISA (anti-CCP2) | 2002 | ~70% | ~98% |
The 2nd generation assay (anti-CCP2) is the current standard and offers major improvements over RF.
Anti-CCP in Other Conditions
Anti-CCP can occasionally be positive in:
- Hepatitis C infection (viral arthritis)
- Lyme disease
- Graves' disease
- SLE and Sjögren's syndrome (with associated erosive joint disease)
Note: In juvenile RA, anti-CCP has very low sensitivity (0.2–3%) and is only positive in the polyarticular, RF-positive subset.
Role in 2010 ACR/EULAR Classification Criteria
The American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) 2010 criteria for RA incorporate ACPA (anti-CCP) as an essential serologic component. A high-positive anti-CCP (>3× upper limit of normal) scores the maximum points in the serology domain.
Summary
- CCP = the antigen (cyclic citrullinated peptide)
- Anti-CCP = the autoantibody detected in blood
- It is the gold standard serologic test for RA, valued for its very high specificity (~98%)
- Positive anti-CCP predicts a more aggressive disease course and can appear years before clinical RA develops
Sources: Henry's Clinical Diagnosis and Management by Laboratory Methods, p. 1194; Textbook of Family Medicine 9e, p. 879; Miller's Review of Orthopaedics 9th Edition
SLE, Myloblastic leukemia
Asking for Preferences
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have rich content from both topics. Let me compile the comprehensive notes.
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Definition
SLE is a generalized autoimmune disease of unknown cause characterized by the production of antibodies to numerous self-antigens — particularly components of the cell nucleus (ANAs). These antibodies bind DNA, RNA, nuclear proteins, and protein–DNA or protein–RNA complexes. Immune complex deposition results in inflammation and vasculitis, causing multiorgan pathology.
Epidemiology
| Feature | Details |
|---|---|
| Peak age | Women of reproductive age (15–40 years) |
| Female:Male ratio | 2:1 before puberty; 4:1 after puberty |
| Prevalence | 1 in 1,000–2,500 general population |
| African American women | Up to 1 in 250 (ages 18–65) |
| 5-year survival | ~90% |
| 15-year survival (treated) | >90% |
Pathophysiology
- Genetic abnormality triggered by environmental factors (infection, stress, sunlight, drugs, toxins)
- Associated with MHC genes: DR2, DR3, DR4, DR5
- Involves B cell, T cell, and monocyte abnormalities
- Key mechanism: antinuclear antibody (ANA) → immune complex deposition → complement activation → tissue damage
Clinical Features (Multisystem)
1. Mucocutaneous (>90% of patients)
- Malar (butterfly) rash — fixed erythema over cheeks, spares nasolabial folds; occurs in ~1/3 of patients, often triggered by sunlight
- Discoid lupus — raised, scarring plaques on face, neck, scalp, ears
- SCLE (Subacute cutaneous LE) — annular or papulosquamous lesions on upper torso; non-scarring
- Photosensitivity — in 1/3 to 2/3 of patients; associated with anti-Ro antibodies (70%)
- Alopecia, oral/nasal/vaginal ulcers, palpable purpura
2. Musculoskeletal
- Non-erosive arthritis in ≥2 peripheral joints (tenderness, swelling, or effusion)
3. Renal (Lupus Nephritis)
- Persistent proteinuria >0.5 g/day or ≥3+
- Cellular casts (RBC, hemoglobin, granular, tubular, or mixed)
- Diagnosed by renal biopsy; can progress to end-stage renal disease
4. Neurologic
- Seizures or psychosis (in absence of other cause)
5. Hematologic
- Hemolytic anemia with reticulocytosis
- Leukopenia (<4,000/mm³ on two occasions)
- Lymphopenia (<1,500/mm³)
- Thrombocytopenia (<100,000/mm³)
6. Serositis
- Pleuritis (pleuritic pain, pleural effusion)
- Pericarditis (documented by ECG, rub, or pericardial effusion)
7. Constitutional symptoms
- Fatigue, malaise, fever, weight loss
ACR Diagnostic Criteria (11 criteria — need ≥4)
| # | Criterion |
|---|---|
| 1 | Malar rash |
| 2 | Discoid rash |
| 3 | Photosensitivity |
| 4 | Oral ulcers |
| 5 | Arthritis (non-erosive, ≥2 joints) |
| 6 | Serositis (pleuritis or pericarditis) |
| 7 | Renal disorder (proteinuria or casts) |
| 8 | Neurologic disorder (seizures or psychosis) |
| 9 | Hematologic disorder (hemolytic anemia, leukopenia, lymphopenia, or thrombocytopenia) |
| 10 | Immunologic disorder (anti-dsDNA, anti-Sm, antiphospholipid antibodies) |
| 11 | Positive ANA |
≥4 of 11 criteria confirms diagnosis, present serially or simultaneously.
Laboratory Findings
| Test | Significance |
|---|---|
| ANA | Most sensitive; positive in >95% of SLE |
| Anti-dsDNA | Highly specific for SLE; correlates with disease activity |
| Anti-Sm | Almost exclusively found in SLE (highly specific) |
| Anti-Ro (SSA) / Anti-La (SSB) | Seen in photosensitivity, neonatal lupus |
| Antiphospholipid antibodies | Risk of thrombosis, miscarriage |
| Complement (C3, C4, CH50) | Decreased during active disease |
| ESR | Elevated (nonspecific) |
| CBC | Hemolytic anemia, leukopenia, thrombocytopenia |
| HIV | Often false positive in SLE |
Treatment
| Target | Drug(s) |
|---|---|
| Mild disease / Maintenance | Hydroxychloroquine (antimalarial), NSAIDs |
| Arthritis/Serositis | Prednisone 0.5 mg/kg/day |
| Nephritis / CNS disease | Prednisone 1 mg/kg/day |
| Severe / Refractory | Cyclophosphamide (IV), Azathioprine, Methotrexate |
| Cutaneous lupus | Sunscreen, topical steroids, hydroxychloroquine, dapsone |
| Antiphospholipid syndrome | Warfarin (INR 2–3) |
| Thrombocytopenia | Methylprednisolone, danazol, splenectomy |
| Pulmonary hemorrhage/TTP | Plasmapheresis |
ACUTE MYELOBLASTIC (MYELOID) LEUKEMIA (AML)
Definition
AML is a clonal malignancy of hematopoietic precursor cells (myeloblasts) characterized by uncontrolled proliferation of immature myeloid cells, arrest of normal differentiation, and accumulation of blasts in the bone marrow and blood, leading to bone marrow failure.
Epidemiology
| Feature | Details |
|---|---|
| Median age | 60 years |
| Incidence | 10/100,000/year in those >60 years |
| Most common AL in | First months of life AND adults >60 years |
| Causative factors | Radiation, benzene, cytotoxic chemotherapy, smoking, viruses |
Pathophysiology
The normal myeloid differentiation pathway (stem cell → myeloblast → promyelocyte → granulocyte) is disrupted by:
- Chromosomal translocations → abnormal fusion proteins
- Mutations in transcription factors and signaling genes
- These block differentiation and promote uncontrolled proliferation
Key mechanism: block in differentiation + uncontrolled proliferation → blast accumulation → bone marrow failure
Clinical Features
- Onset resembles acute infection: fever, ulcerations of mucous membranes (mouth, throat)
- Signs of bone marrow failure:
- Anemia → fatigue, pallor
- Neutropenia → recurrent infections
- Thrombocytopenia → bleeding/bruising
- Lymphadenopathy, splenomegaly, hepatomegaly — not pronounced (unlike ALL)
- Marked prostration and malaise
- Rapidly progressive if untreated
Diagnosis
Peripheral blood / Bone marrow
- ≥20% blasts in marrow or blood confirms AML
- Myeloblasts: central nuclei, fine uncondensed chromatin, prominent nucleoli (3–5), variable cytoplasm ± granules
- Auer rods — eosinophilic rod-like cytoplasmic inclusions derived from myeloperoxidase-rich granules — pathognomonic of AML (especially AML-M3)
Cytochemistry
| Stain | Positive in |
|---|---|
| MPO (myeloperoxidase) | Myeloblasts |
| Sudan Black B (SBB) | Myeloblasts |
| Chloroacetate esterase (CAE) | Granulocytic series |
| α-naphthyl acetate esterase (ANAE) | Monoblasts (inhibited by NaF) |
Immunophenotype (Flow Cytometry)
- MPO, CD13, CD33, CD117 — myeloid markers
- CD34 — primitive progenitor
- CD64, CD68, CD36, antilysozyme — monocytic differentiation
WHO Classification (Main Categories)
| Category | Notes |
|---|---|
| AML with recurrent cytogenetic abnormalities | Favorable (core binding factor) or unfavorable |
| AML with myelodysplasia-related changes | Prior MDS or dysplastic morphology |
| Therapy-related AML | Post-chemotherapy or radiation |
| AML, not otherwise specified (NOS) | Classified by FAB morphology |
Key Cytogenetic Subtypes
| Translocation | Fusion Gene | Prognosis | Notes |
|---|---|---|---|
| t(8;21) | RUNX1-RUNX1T1 | Good | Core binding factor; 10% of AML |
| inv(16) / t(16;16) | CBFB-MYH11 | Good | Core binding factor; 10% of AML |
| t(15;17) | PML-RARA | Good | Acute promyelocytic leukemia (APL/M3); hematologic emergency (DIC risk); responsive to ATRA |
| t(9;11) | MLLT3-KMT2A | Poor | Monocytic differentiation, gingival hypertrophy |
| FLT3-ITD | — | Poor | Most common mutation in AML (~30%) |
| NPM1 mutation | — | Good (if FLT3-negative) | Most common in de novo AML |
FAB Classification (Morphologic — still used)
| FAB | Name | Key Feature |
|---|---|---|
| M0 | Minimally differentiated AML | MPO negative morphologically |
| M1 | AML without maturation | Blasts >90% |
| M2 | AML with maturation | Blasts >20%, some maturation |
| M3 | Acute promyelocytic (APL) | Auer rods; DIC; t(15;17); ATRA-responsive |
| M4 | Acute myelomonocytic | Both granulocytic and monocytic |
| M4Eo | With eosinophilia | inv(16) |
| M5 | Acute monocytic | Gingival hypertrophy |
| M6 | Erythroleukemia | >50% erythroid precursors |
| M7 | Megakaryoblastic | Down syndrome; platelet markers |
Treatment
| Phase | Regimen |
|---|---|
| Induction | "7+3": Cytarabine (ara-C) × 7 days + Daunorubicin × 3 days |
| Consolidation (CBF AML) | High-dose cytarabine (HiDAC) |
| APL (M3) | ATRA (all-trans retinoic acid) + Arsenic trioxide — highly effective |
| FLT3-mutated AML | Midostaurin + chemotherapy |
| Relapsed/refractory | Allogeneic stem cell transplant (HSCT) |
| Supportive | Antibiotics, antifungals, transfusions, growth factors |
Key Differences: SLE vs AML
| Feature | SLE | AML |
|---|---|---|
| Type | Autoimmune disease | Hematologic malignancy |
| Pathology | Immune complex deposition | Clonal myeloblast proliferation |
| Key marker | Anti-dsDNA, anti-Sm | Auer rods, ≥20% blasts |
| Affected population | Young women (15–40) | Elderly (median 60 years) |
| Treatment backbone | Hydroxychloroquine, steroids | Cytarabine + anthracycline |
Sources: Textbook of Family Medicine 9e, pp. 899–902; Henry's Clinical Diagnosis and Management by Laboratory Methods, pp. 1194–1200; Tietz Textbook of Laboratory Medicine 7th Ed.
Can sle cause Myloblastic leukemia
Finding Sources
Searching PubMed
"systemic lupus erythematosus" AND "acute myeloid leukemia"
Finding Sources
Searching PubMed
"systemic lupus erythematosus" AND malignancy AND leukemia
Finding Sources
Searching PubMed
"lupus erythematosus" AND cancer AND hematologic
Reading Article
Reading Article
Finding Sources
Finding Sources
Reading File
This is a nuanced and clinically important question. Here is the evidence-based answer:
Can SLE Cause Myeloblastic (Acute Myeloid) Leukemia?
Short Answer
SLE itself does not directly cause AML, but SLE patients carry a significantly elevated risk of developing AML and other hematologic malignancies — through two distinct pathways: the disease itself and its treatment.
1. SLE Disease-Related Risk (Independent of Treatment)
A large systematic review and meta-analysis of 48 cohort studies involving 247,575 SLE patients (Zhang et al., Frontiers in Oncology, 2022 — PMID 35600353) found:
- Overall cancer risk in SLE: RR = 1.62 (95% CI 1.47–1.79)
- Hematologic malignancy risk — SLE was a significant risk factor for 5 hematologic cancers:
- Lymphoma
- Hodgkin's lymphoma
- Non-Hodgkin lymphoma
- Leukemia ✓
- Multiple myeloma
- The strongest causal link was confirmed for lymphoma via Mendelian randomization
Why does SLE increase cancer risk?
| Mechanism | Explanation |
|---|---|
| Chronic immune dysregulation | Persistent B and T cell activation → oncogenic signaling |
| Impaired immune surveillance | Abnormal immune function fails to detect and eliminate malignant clones |
| Chronic inflammation | Promotes DNA damage and genomic instability |
| Antinuclear antibody burden | May impair normal cell apoptosis and DNA repair mechanisms |
2. Treatment-Related AML (Therapy-Related AML — t-AML)
This is the stronger and better-documented mechanism linking SLE to AML specifically.
Cyclophosphamide — the key culprit
Cyclophosphamide is a cornerstone of SLE treatment (used for lupus nephritis, severe CNS lupus, vasculitis). It is a known leukemogen:
"The standardized incidence ratio of acute myelocytic leukemia was 59.0 above the cumulative cyclophosphamide exposure threshold of 36 g." — Brenner and Rector's The Kidney
| Cancer type | Standardized Incidence Ratio (SIR) post-cyclophosphamide |
|---|---|
| Acute myelocytic leukemia | 59.0× above expected |
| Bladder cancer | 9.5× |
| Non-melanoma skin cancer | 5.2× |
Key features of therapy-related AML:
- Latent period: averages 6.9 to 18.5 years after cyclophosphamide exposure — patients require lifelong screening
- The risk threshold is as low as 36 g cumulative cyclophosphamide (equivalent to 2 mg/kg/day for just 8 months)
- AML from cyclophosphamide is classified as WHO "therapy-related AML" — a recognized and distinct entity
- Typically presents with complex cytogenetics (monosomy 5, monosomy 7) and carries a poor prognosis
"Later development of hematologic malignancies (rare) and premature ovarian failure (common) can result from cyclophosphamide use." — Textbook of Family Medicine 9e, p. 901
3. Clinical Cases in the Literature
A case report (PMID 35106248) documented a 62-year-old woman with concurrent SLE and AML, describing the co-existence as a rare but recognized association — though whether causally linked or coincidental remains difficult to establish in individual cases.
A second case (PMID 37126116) reported SLE developing after bone marrow transplantation for AML, suggesting the relationship can also occur in reverse — immune reconstitution triggering autoimmunity.
Summary
| Pathway | Evidence | Risk Level |
|---|---|---|
| SLE disease itself → leukemia | Meta-analysis (RR elevated, but less strong for AML specifically vs. lymphoma) | Moderately increased |
| Cyclophosphamide treatment → therapy-related AML | Very well established; SIR of 59× | Strongly elevated |
| Direct causation (SLE → AML) | Not proven; likely coincidental or immune-dysregulation mediated | Rare, uncertain |
The most clinically important takeaway: Any SLE patient who has received cyclophosphamide should be monitored lifelong for development of AML and other malignancies, given the very long latent period (up to 18 years). The preferred modern approach is to minimize cumulative cyclophosphamide dose and use steroid-sparing alternatives (mycophenolate mofetil, azathioprine, belimumab) wherever possible to reduce this risk.
This is a shared conversation. Sign in to Orris to start your own chat.